Success Metrics

Clinical Success Rate

60.0%

Based on 3 completed trials

Completion Rate

60%(3/5)

Active Trials

3(30%)

Results Posted

100%(3 trials)

Terminated

2(20%)

Phase Distribution

Ph phase_1

50%

Ph phase_2

10%

Ph phase_3

30%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

5(55.6%)

Phase 2Efficacy & side effects

1(11.1%)

Phase 3Large-scale testing

3(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Completed(3)

Terminated(2)

Detailed Status

Completed3

Terminated2

Active, not recruiting2

Enrolling by invitation2

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

60.0%

Most Advanced

Phase 3

Trials by Phase

Phase 15 (55.6%)

Phase 21 (11.1%)

Phase 33 (33.3%)

Trials by Status

completed330%

recruiting110%

terminated220%

active_not_recruiting220%

enrolling_by_invitation220%

Recent Activity

3 active trials

Showing 5 of 10

enrolling_by_invitation

An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy

NCT06270719

recruitingphase_1

A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

NCT04626674

active_not_recruitingphase_2

A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)

NCT06128564

enrolling_by_invitationphase_3

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

NCT05967351

terminatedphase_1

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)

NCT06241950

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT06270719

An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy

Enrolling By Invitation

NCT04626674Phase 1

A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Recruiting

NCT06128564Phase 2

A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)

Active Not Recruiting

NCT05967351Phase 3

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

Enrolling By Invitation

NCT06241950Phase 1

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)

Terminated

NCT06597656Phase 1

A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74

Terminated

NCT05096221Phase 3

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Completed

NCT05881408Phase 3

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Active Not Recruiting

NCT03375164Phase 1

A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Completed

NCT03769116Phase 1

A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)

Completed

All 10 trials loaded

Drug Details

Intervention Type: GENETIC
Total Trials: 10